Drug Discovery Services Market worth $27.23 billion in 2030
The report "Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030 ", is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a significant CAGR of 10.7%.
Browse 575 market data Tables and 64 Figures spread through 454 Pages and in-depth TOC on "Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html
Due to a number of factors, including initiatives for research on rare diseases and orphan drugs, the high cost of in-house drug development, the growing R&D expenditure from drug pharmaceutical and biopharmaceutical companies, and the growing R&D pipeline necessitating increased outsourcing of analytical testing, the market is expanding more quickly. Players in this market are anticipated to have growth prospects due to technological developments, the introduction of new drug discovery approaches, patent expiration, and the rise in end-user demand for specialized testing services.
The chemistry services segment dominated the drug discovery services type segment in 2024
The market is segmented by type into chemistry services, and biology services. The chemistry services segment dominated the market in 2024. The chemistry services hold a significant share in the market owing to the introduction of technologies such as combinatorial chemistry and structure-based drug design. Rising demand for high-quality, safe, and effective drugs to support growth also support the analytical chemistry services market growth.
The biologics segment is the fastest growing segment of the drug type segment in the drug discovery services market in 2024.
The drug type segment is sub-segmented into biologics and small molecules. Biopharmaceutical companies are focusing on developing biologics for various therapeutic areas, development of biologics, high cost of biologics, complexity of biologic drugs and safety and manufacturing issues related to biologics are all driving this segment growth. Biotech pharma companies are outsourcing biologic drug discovery and development to experienced service providers.
Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period of 2025-2030
The drug discovery services market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the market due to a presence of well-established CROs, rising R&D expenditure, and rapid growth in the biosimilar and biologics markets. Asia-Pacific (APAC) is witnessing rapid growth, due to the expanding pharmaceutical and biopharmaceutical industry, the rising number of CROs, and less-stringent regulations for drug discovery processes in several APAC countries.
The report profiles key players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
